More precisely, in some cancers, PD-1 inhibition does not decrease tumor volume, but, in combination with anti-TGF-β, PD-1 blockade significantly improves outcome of treatment compared to treatment with anti-TGF-β alone. Here, TGFB1 is linked to cancer.